1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Gilead's Trodelvy Surpasses Investors' Low Bar At ASCO, But Faces A Commercial Climb

 
• By Jessica Merrill

The Phase III TROPICS-02 study in HR-positive/HER2-negative breast cancer was successful, but data for rival drug Enhertu overshadowed the results.

rock climbing
Gilead appears to have a tough climb for Trodelvy in HR+/HER2- breast cancer • Source: Shutterstock

Gilead Sciences, Inc. prepared investors to be underwhelmed by the Phase III data results from TROPICS-02, testing Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy in heavily pre-treated HR-positive/HER2-negative metastatic breast cancer. So the data – presented at the American Society of Clinical Oncology (ASCO) annual meeting on 4 June – were about what investors were expecting or slightly better.

Nonetheless, impressive Phase III data at ASCO for a different antibody drug conjugate (ADC), AstraZeneca PLC/Daiichi Sankyo Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.